• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对《瑞德西韦治疗 COVID-19：肺部给药与静脉给药联合使用可能带来额外益处》的勘误

Correction to: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit.

作者信息

Sun Duxin

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.

出版信息

AAPS J. 2020 Aug 2;22(5):102. doi: 10.1208/s12248-020-00483-8.

DOI:10.1208/s12248-020-00483-8
PMID:32743771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7396203/
Abstract

During the proofing process, the misspelling of "additional" occurred while changing the title of the article. The complete title should be "Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit".

摘要

在校对过程中，在更改文章标题时出现了“additional”的拼写错误。完整的标题应该是“瑞德西韦治疗COVID-19：肺部给药与静脉给药联合使用可能带来额外益处”。

相似文献

1
Correction to: Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit.对《瑞德西韦治疗 COVID-19：肺部给药与静脉给药联合使用可能带来额外益处》的勘误
AAPS J. 2020 Aug 2;22(5):102. doi: 10.1208/s12248-020-00483-8.
2
Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19.《瑞德西韦的修正：对其发现与研发历程的回顾，该历程导向了针对治疗 COVID-19 的人体临床试验》
ACS Cent Sci. 2020 Jun 24;6(6):1009. doi: 10.1021/acscentsci.0c00747. Epub 2020 Jun 16.
3
Ryan White CARE Act Title IV programs: a preliminary characterization of benefits and costs.《瑞安·怀特艾滋病紧急救援计划》第四章项目：效益与成本的初步描述
AIDS Public Policy J. 2005 Fall-Winter;20(3-4):108-25.
4
Correction: Should Remdesivir Be Used for the Treatment of Patients With COVID-19?更正：瑞德西韦是否应用于治疗新型冠状病毒肺炎患者？
Ann Intern Med. 2021 May;174(5):735-736. doi: 10.7326/L21-0138. Epub 2021 Mar 16.
5
Correction: Remdesivir for Adults With COVID-19.更正：瑞德西韦用于成人新冠病毒肺炎治疗。
Ann Intern Med. 2021 May;174(5):736. doi: 10.7326/L21-0130. Epub 2021 Mar 16.
6
Correction: Should Remdesivir Be Used for the Treatment of Patients With COVID-19?更正：瑞德西韦是否应用于治疗新型冠状病毒肺炎患者？
Ann Intern Med. 2021 Jul;174(7):1040. doi: 10.7326/L21-0258.
7
Covid-19: US should end Gilead's monopoly on producing remdesivir, report says.报告称，新冠疫情：美国应终结吉利德对瑞德西韦生产的垄断。
BMJ. 2020 Sep 10;370:m3537. doi: 10.1136/bmj.m3537.
8
Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19.关于瑞德西韦治疗COVID-19的系统评价附录
West J Emerg Med. 2020 May 22;21(4):742-743. doi: 10.5811/westjem.2020.5.48121.
9
ICER update to pricing models of remdesivir for COVID-19.针对COVID-19的瑞德西韦定价模型的ICER更新。
PharmacoEcon Outcomes News. 2020;857(1):2. doi: 10.1007/s40274-020-6939-6. Epub 2020 Jul 11.
10
Correction to: COVID-19 and the elderly patients: insights into pathogenesis and clinical decision-making.对《COVID-19与老年患者：发病机制及临床决策洞察》的勘误
Aging Clin Exp Res. 2020 Sep;32(9):1909. doi: 10.1007/s40520-020-01700-2.

引用本文的文献

1
Identification of CYFIP2 Arg87Cys Ligands via In Silico and In Vitro Approaches.通过计算机模拟和体外实验方法鉴定CYFIP2 Arg87Cys配体
Biomedicines. 2024 Feb 21;12(3):479. doi: 10.3390/biomedicines12030479.
2
Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.瑞德西韦和地塞米松用于南非COVID-19治疗的成本效益
Open Forum Infect Dis. 2021 Jan 29;8(3):ofab040. doi: 10.1093/ofid/ofab040. eCollection 2021 Mar.